Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Anakinra (Primary) ; Capecitabine; Eribulin; Paclitaxel; Vinorelbine
- Indications Advanced breast cancer
- Focus Adverse reactions; Biomarker
- 07 Jun 2016 Results of safety and immunologic activity of anakinra (n=11) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 13 Jan 2016 Planned End Date changed from 1 Jul 2014 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 13 Jan 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.